- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02562430
Neurobiological Underpinnings of Placebo Response in Depression
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The objective of this pilot study is to investigate possible dopaminergic mechanisms underlying the placebo response in MDD.
We expect that mesolimbic DA mechanisms implicated in reward anticipation, reinforcement learning, and expectation play a critical role in mediating placebo responses in MDD. A better understanding of the neurobiological basis of placebo has enormous potential on different levels. On a clinical level, the understanding of placebo mechanisms could lead to a number of applications for therapeutic purposes, such as developing drugs that could enhance the effects of a therapeutic relationship or accelerate the onset of action of an antidepressant by manipulating the placebo-related mechanisms, even if the patient is hopeless or severely anhedonic. On a level of clinical trial innovation, if we confirm the role of dopamine in placebo response and we comprehend how the placebo response mechanistically takes place, this could lead to developing new drugs that could block the placebo effects in clinical trial participants and greatly decrease if not eliminate the placebo effect nested even in those subject who are drug responders, therefore increasing the effect size and decreasing the sample size of studies. Moreover if we can identify biosignatures of placebo effect and use them to predict response, we could potentially enrich samples with subjects who are less likely to be placebo responders and again this would result in increased signal detection in a clinical trial. Finally, with this initial study we plan to lay the foundation for other studies to investigate how this dopaminergic circuitry is affected by other treatments, such as psychotherapy, and what are the changes that are similar or different between antidepressants, placebo and specific forms of psychotherapy, transcranial magnetic stimulation, electroconvulsive therapy or deep brain stimulation.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Depression Clinical and Research Program at Massachusetts General Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria
In addition to fulfilling the diagnostic criteria for MDD, the following conditions must be met for patient eligibility:
- Written informed consent
- Men or women aged 18 to 60 years old
- A score of 16 or greater on the Hamilton Depression Rating Scale -32 items (HAM-D- 32)
- Continuing to meet criteria for current MDD at baseline and Clinical Global Impression Improvement (CGI) scores ≤ 3 (i.e. minimally improved or less) from the screen to the baseline visit
- Only one failed one prior antidepressant in the current episode or are currently taking an antidepressant as defined by the MGH-ATRQ, in the current episode and are willing to take bupropion or placebo as augmentation, since we are using subjects as their own controls and we are comparing changes within subjects. Subjects with secondary anxiety disorders, like panic, GAD or simple phobia will be allowed, in order to make the population studied more representative of the general population of MDD.
Exclusion Criteria
- Pregnant women or women of child bearing potential not using a medically accepted means of contraception.
- Serious suicide or homicide risk.
- Unstable medical illnesses, any history of seizure disorder.
- The following DSM-IV diagnoses: a) organic mental disorders; b) substance use disorders, including alcohol abuse, within the last year; c) psychotic disorders; d) bipolar disorder; e) acute bereavement; f) severe borderline or antisocial personality disorder; g) history of eating disorder unless if in remission for ≥5 years prior to screening and presenting no current electrolyte abnormalities; h) current primary diagnoses of panic disorder, social phobia, PTSD, GAD, or OCD; i) mood congruent or mood incongruent psychotic features.
- History of hepatic impairment or congestive heart failure.
- Any history of abuse of stimulants or opiates.
- Currently taking any exclusionary medications (i.e., antipsychotics, anticonvulsants, stimulants, dopaminergic agents), potential augmenting agents (e.g., T3, SAMe, St. John's Wort, lithium,). Gabapentin and pregabalin are allowed. Patients must have either no antidepressant treatment or stable (for at least 4 weeks prior to screening). No dose changes are allowed during the study. Monoamine oxidase inhibitors are excluded. Concomitant use of trazodone (up to 200 mg daily) is allowed. In agreement with patient's treating provider and under clinical monitoring, exclusionary drugs can be tapered and washed out prior to baseline visit.
- Any investigational psychotropic drug within the last year.
- Subjects who have not responded to two or more antidepressant trials of adequate doses (e.g., fluoxetine 40 mg/day or higher) and duration (e.g., ≥6 weeks) over the past five years according to the ATRQ.
- History of inadequate response/poor tolerability to bupropion.
- Subjects with medical contraindications to bupropion (e.g., history of seizures, uncontrolled electrolyte imbalance due to eating disorders, etc.) unless stable for 8 weeks prior to screening and there will be no changes during participation in the study.
- Any unstable concomitant form of psychotherapy (depression-focused). Concomitant psychotherapy would be allowed if the frequency and the modality have been stable for the 8 weeks prior to screening and there will be no changes during the participation to the study
- Receiving or have received during the index episode VNS, ECT or rTMS.
- Color-blindness for blue or green (see fMRI task).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Active Treatment
12.5 % will be randomized to Welbutrin XL in phase 1 of the study.
|
12.5% of participants will receive Welbutrin XL in phase 1 of the study.
Andra namn:
|
Aktiv komparator: Placebo Group
87.5% will be randomized to receive placebo in phase 1 of the study.
|
87.5% of subjects will be randomized to placebo in phase 1 of the study.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
HAM-D 32
Tidsram: 8 weeks
|
8 weeks
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Clinical Global Impressions
Tidsram: 8 weeks
|
8 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Cristina Cusin, MD, Massachusetts General Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2014P000889
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Depression
-
ProgenaBiomeRekryteringDepression | Depression, postpartum | Depression, ångest | Depression Måttlig | Depression Svår | Klinisk depression | Depression i remission | Depression, Endogen | Depression KroniskFörenta staterna
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRekryteringDepression | Depression Måttlig | Depression Svår | Depression MildFörenta staterna
-
University of California, San FranciscoRekryteringDepression Måttlig | Depression Mild | Depression, tonåringFörenta staterna
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.Rekrytering
-
Washington University School of MedicineAvslutadBehandling Resistent depression | Senlivsdepression | Geriatrisk depression | Refraktär depression | Terapiresistent depressionFörenta staterna, Kanada
-
Baylor College of MedicineUniversity of TexasRekryteringDepression | Depression Måttlig | Depression Svår | Självmord och självskada | Depression i tonåren | Depression MildFörenta staterna
-
University of Cape TownNational Institute of Mental Health (NIMH)AvslutadPostpartum depression | Klinisk depression | Måttlig depressionSydafrika
-
Gerbera Therapeutics, Inc.Har inte rekryterat ännuPostpartum depression | Depression, postpartum | Postnatal depression | Post-partum depression | Post-Natal depressionFörenta staterna
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoAvslutadDepression Måttlig | Depression MildFörenta staterna, Dominikanska republiken
-
Charite University, Berlin, GermanyAvslutadBehandling Resistent depression | Depression, unipolär | Depression KroniskTyskland
Kliniska prövningar på Welbutrin XL
-
NovartisAvslutadMetaboliskt syndromKalkon
-
DePuy OrthopaedicsAvslutadTotal höftprotesplastik | Skadlig lokal vävnadsreaktionFörenta staterna
-
AlyatecAvslutadAstma | AllergiFrankrike
-
Indiana UniversityAvslutadGlioblastoma Multiforme | Höggradig Gliom | Anaplastiskt astrocytom | Malign hjärntumörFörenta staterna
-
Dana-Farber Cancer InstituteAvslutad
-
Massachusetts General HospitalAvslutadMultipelt myelomFörenta staterna
-
Massachusetts General HospitalExelixisAvslutadGallgångscancer | Intrahepatisk kolangiokarcinom | Kolangiokarcinom i den extrahepatiska gallgångenFörenta staterna
-
TC Erciyes UniversityAvslutad
-
EndologixAbbott Medical DevicesAvslutadAbdominal aortaaneurysmFörenta staterna